STAT Plus: Pharmalittle: Trump grows frustrated over drug pricing; FDA enforcement declines under Trump
Good morning, everyone, and how are you today? We are doing just fine, thank you, courtesy of a shiny sun and cool breeze enveloping the Pharmalot campus. As usual, we are brewing cups of stimulation and foraging for items of interest, which we have assembled below as you can see. One quick note: Given the pending holiday on this side of the pond, we will suspend our morning newsletter until Monday. For those of you who have a scheduled respite, we hope you enjoy. Meanwhile, have a wonderful day. …
As President Trump presses to make health care a central plank of his 2020 reelection bid, he is displaying mounting frustration with those he thinks are thwarting his ability to deliver on a major campaign promise: lowering drug prices, The Washington Post tells us. That has included Health and Human Services Secretary Alex Azar, a former drug executive who until very recently pushed back on proposals to import lower-cost drugs from Canada and negotiate drug prices in Medicare. Under pressure, Azar is reversing some of his positions.
Continue to STAT Plus to read the full story…
